Other

Altavant Sciences Gmbh

Ohr Pharmaceutical Inc.

Roy C Levitt, Jr

Michael McLane

Xuehai Zhang

Charles W Gilbert

Eric Chellquist

Kyle Armbruster

Mary Doubleday

Methods and compositions for treating inflammatory disorders of the lower airways are disclosed herein. In one aspect, a method for treating an inflammatory disorder of lower airways in a human subject in need thereof is disclosed, including administering directly to the lower airways in the human subject an effective amount of anakinra, where the effective amount of anakinra is 0.01 mg to 100 mg per day.

Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors

The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the expression and/or activity of a proinflammatory cytokine or fragment thereof, preferably in a human. The proinflammatory cytokine contemplated by the invention includes IL-1, IL-6, IL-8 and TNF-alpha. The present invention describes a kit comprising a delivery device and a pharmaceutical composition for administration of the agent. The pharmaceutical composition includes at least one proinflammatory cytokine inhibitor, optionally one or more additional active ingredients, and at least one pharmaceutically active carrier. The delivery device further comprises a nebulizer, an inhaler, a powder dispenser, an intrapulmonary aerosolizer and a sub-miniature aerosolizer.

The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation.

Polymorphic and amorphous salt forms of squalamine dilactate

Growing community of inventors

Miami, FL, United States of America

Roy C Levitt, Jr